Search

Search Constraints

You searched for: Author/Creator Barbui, Tiziano

Search Results

1. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. (16th August 2014)

2. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Issue 4 (30th October 2013)

3. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Issue 4 (30th October 2013)

4. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. (10th April 2013)

5. A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: A propensity‐matched study. Issue 11 (29th July 2017)

6. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Issue 4 (April 2022)

7. Association between inhibitors of the renin–angiotensin system and lung function in elderly patients recovered from severe COVID-19. (18th September 2021)

8. Cerebral vein thrombosis in patients with Philadelphia‐negative myeloproliferative neoplasms An European Leukemia Net study. Issue 11 (31st July 2014)

9. Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases. Issue 12 (10th September 2021)